We use cookies to make your visit to our website as pleasant as possible. If you continue to use the website, you agree to our privacy policy and to the use of cookies. More information about cookies and how ImpediMed uses them is available here.
Accept Cookies
NAPBC STANDARDS
Meet Accreditation Standards with a Lymphedema Prevention Program
Learn More

Lymphedema is a Risk of Breast Cancer Treatment that Can Have a Devastating Impact to Breast Cancer Survivor Quality of Life

300k

newly diagnosed breast cancer patients every year in the U.S.1

1 in 5

breast cancer patients will be impacted by lymphedema2

82%

of breast cancer patients are at risk of arm lymphedema due to their treatment3

Do you feel lymphedema has impacted your quality of life?
PATIENT VOICES
“
”
91% of patients believe that care teams should offer cancer patients a Lymphedema Prevention Program
Source: 2022 ImpediMed Lymphedema Awareness Study
“
”
I have been fighting cancer for over 25 years now and developing secondary lymphedema has by far been the worst part.
Source: 2022 ImpediMed Lymphedema Awareness Study
“
”
Surviving with hand and arm lymphedema after breast cancer makes me second guess what I can and can't do on a daily basis.
Source: 2022 ImpediMed Lymphedema Awareness Study
“
”
I have been in cancer remission for over 10 years but I currently spend about 3 hours per day managing my lymphedema and wear compression 24/7.
Source: 2022 ImpediMed Lymphedema Awareness Study
Learn More About Patient Resources

ImpediMed SOZO NCCN Clinical Practice Guidelines

CLINICAL PRACTICE GUIDELINES

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship

The NCCN Guidelines® are consistent about the importance of early detection of lymphedema and use of an objective tool, such as bioimpedance spectroscopy.

Learn More

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed March 29, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

ImpediMed SOZO NCCN Clinical Practice Guidelines

CLINICAL EVIDENCE

BIS Technology Sets the Standard of Care for Lymphedema Detection

In PREVENT, the largest randomized controlled trial (RCT) for lymphedema prevention in breast cancer patients, 92% of patients with early detection using BIS and intervention did not progress to chronic lymphedema.

Discover the Power of BIS Technology

EARLY DETECTION & INTERVENTION FOR LYMPHEDEMA CARE

Improving Patient Outcomes with a Lymphedema Prospective Care Model

Using our SOZO Digital Health Platform with L-Dex, ImpediMed partners with you to implement a Lymphedema Prevention Program (LPP) to help detect lymphedema in breast cancer patients at the early stage, so that it can be treated and stopped from progressing to a lifelong condition.

Learn More About LPP

LATEST NEWS & UPDATES

References

  1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program Cancer Stat Facts 2023. National Institutes of Health, 2023.
  2. Gillespie TC, et al. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018 Aug; doi: 10.21037/gs.2017.11.04.
  3. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. Atlanta: American Cancer Society; 2019.
  4. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology 2022.